Isabelle Cousineau

Sep 7, 2023 | cell.com | Laurence Buisseret |David Allard |Isabelle Cousineau |Pavel Chrobak

Highlights•A2AR deficiency triggers spontaneous obesity, inflammation, and NASH-HCC in mice•Myeloid- and hepatocyte-derived A2AR signaling restrains HCC development•Steatohepatitis impairs the anti-HCC activity of A2AR pharmacological blockade•Low ADORA2A gene expression predicts poor survival in HCC patientsSummaryInhibition of adenosine A2A receptor (A2AR) is a promising approach for cancer immunotherapy currently evaluated in several clinical trials.